



EMLc

ATC codes: P01CB02

Indication	Cutaneous leishmaniasis <span>ICD11 code: 1F54.1</span>
INN	Sodium stibogluconate
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial
EML status history	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1984 (TRS 722) Removed in 1989 (TRS 796) Added in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Sodium stibogluconate</a>
DrugBank	<a href="#">Sodium stibogluconate</a>

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for sodium stibogluconate / meglumine antimoniate on the EML and EMLc be amended to list each medicine separately with updated dosage form descriptions as follows: Sodium stibogluconate: Injection: 100 mg/mL in 30 mL vial Meglumine antimoniate: Injection: 1.5 g/5 mL in 5 mL ampoule

